Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 142 | 33% |
| 2020 | 3 | 135 | 36% |
| 2021 | 3 | 171 | 39% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 4 | 485−4.3%/yr | −4.3%/yr | 0.3 | 0% | 620 in 2030+4.1%/yr |
| New York | 8 | 452−3.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 13 | 399+11%/yr | +11%/yr | 0.40.7× | 0% | 600 in 2030+7.1%/yr |
| Stroke thrombectomy |
DBS & VNS in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
| 2024 |
| 206 |
| 45% |
| 2025 est. | ≈ 210 | – |
| 2026 est. | ≈ 220 | – |
| 2022 | 5 | 161 | 41% |
| 2023 | 3 | 131 | 43% |
| 2024 | 4 | 206 | 45% |
| 2025 from claims | – | 210 170–247 | 46% |
| 2026 forecast | – | 223 175–281 | 46% |
| 2027 forecast | – | 237 176–313 | 47% |
| 2028 forecast | – | 251 178–347 | 47% |
| 2029 forecast | – | 267 181–382 | 47% |
| 2030 forecast | – | 283 185–420 | 48% |
In 2025, 22% inpatient hospital, 78% hospital outpatient.
| −3.8%/yr |
| 0.2 |
| 0% |
| 480 in 2030+0.9%/yr |
| Massachusetts | 6 | 233−7.5%/yr | −7.5%/yr | 0.2 | 0% | 270 in 2030+2.6%/yr |
| 15 |
| 346+3.2%/yr |
| +3.2%/yr |
| 0.30.7× |
| 0% |
| 330 in 2030−1%/yr |
| CSF shunts | 0 | 134−11%/yr | −11%/yr | 0.10.6× | 0% | 120 in 2030−1.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 31% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 6 companies reported engagement with New Jersey’s surgeons worth $31K in consulting, speaking, meals and travel tied to these products, about $7,770 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.